State-owned China Central Television (CCTV) has finally shown a National Basketball Association (NBA) game after 18 months, signaling the latest de-escalation of tensions between the parties.
CCTV, which has exclusive TV rights in China for the NBA, aired the Los Angeles Clippers and the Utah Jazz on 29th March, according to the network’s broadcasting schedule.
CCTV last aired a game in October 2020.
In October 2019, the broadcaster halted league coverage in reaction to a tweet from Daryl Morey, the general manager of the Houston Rockets at the time, expressing support for anti-government demonstrators in Hong Kong.
In addition to the items being removed from stores, Chinese sponsors have discontinued their relationships with the NBA and its teams. NBA commissioner Adam Silver predicted the league would lose "hundreds of millions of dollars" as a result of the aftermath in February 2020.
Following an initial suspension, NBA games were made available on Tencent's streaming service in China.


Indian Sugar Stocks Surge on Tight Supply, Festive Demand
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p
US-Canada Tariff War Escalates With 50% Auto Duties
Iran Allows Iraqi Oil Tankers Through Strait of Hormuz
Trump Draws Cheers at Ryder Cup as U.S. Trails Europe After Opening Day
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers
Europe EV Sales Surge as High Fuel Prices Drive Demand
White House Defends Trump’s FIFA Peace Prize Amid Global Criticism
UK Economy Shows Strength as Burnham Gets Early Boost
Spying, Southampton and economic pressure cooker of the ‘richest match in football’
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7%
California Seeks Paramount Divestitures in Warner Bros. Merger
Trump Urges Hall of Fame Induction for Roger Clemens Amid Renewed Debate
U.S. Eases Iran Team Travel Restrictions Ahead of Seattle World Cup Match
Trump’s U.S. Open Visit Delays Final, Fans Face Long Security Lines
Asian Currencies Steady as Dollar Hovers Near Multi-Month Lows
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 



